Instalco AB (publ) (STO:INSTAL)
Sweden · Delayed Price · Currency is SEK 25.74
+0.04 (0.16%)
Aug 1, 2025, 5:29 PM CET
Achilles Therapeutics Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 13,557 | 13,690 | 14,279 | 12,063 | 8,890 | 7,122 | Upgrade |
Revenue | 13,557 | 13,690 | 14,279 | 12,063 | 8,890 | 7,122 | Upgrade |
Revenue Growth (YoY) | -4.00% | -4.13% | 18.37% | 35.69% | 24.82% | 25.12% | Upgrade |
Cost of Revenue | 6,380 | 6,456 | 7,215 | 6,186 | 4,552 | 3,720 | Upgrade |
Gross Profit | 7,177 | 7,234 | 7,064 | 5,877 | 4,338 | 3,402 | Upgrade |
Selling, General & Admin | 6,143 | 6,077 | 5,742 | 4,773 | 3,496 | 2,672 | Upgrade |
Other Operating Expenses | -94 | -95 | -83 | -48 | -58 | -33 | Upgrade |
Operating Expenses | 6,610 | 6,542 | 6,176 | 5,106 | 3,636 | 2,774 | Upgrade |
Operating Income | 567 | 692 | 888 | 771 | 702 | 628 | Upgrade |
Interest Expense | -238 | -255 | -151 | -50 | -15 | -13 | Upgrade |
Interest & Investment Income | 51 | 51 | 93 | 38 | 23 | 23 | Upgrade |
Currency Exchange Gain (Loss) | - | - | -20 | -56 | -17 | -12 | Upgrade |
Other Non Operating Income (Expenses) | 23 | 1 | -29 | -20 | -13 | -7 | Upgrade |
EBT Excluding Unusual Items | 403 | 489 | 781 | 683 | 680 | 619 | Upgrade |
Merger & Restructuring Charges | -9 | -9 | -12 | -12 | -11 | -10 | Upgrade |
Impairment of Goodwill | -29 | -29 | - | - | - | - | Upgrade |
Other Unusual Items | 26 | 35 | 23 | 25 | 31 | -14 | Upgrade |
Pretax Income | 391 | 486 | 792 | 696 | 700 | 595 | Upgrade |
Income Tax Expense | 100 | 122 | 177 | 145 | 142 | 133 | Upgrade |
Earnings From Continuing Operations | 291 | 364 | 615 | 551 | 558 | 462 | Upgrade |
Minority Interest in Earnings | -19 | -19 | -14 | -31 | -12 | -6 | Upgrade |
Net Income | 272 | 345 | 601 | 520 | 546 | 456 | Upgrade |
Net Income to Common | 272 | 345 | 601 | 520 | 546 | 456 | Upgrade |
Net Income Growth | -50.18% | -42.60% | 15.58% | -4.76% | 19.74% | 23.24% | Upgrade |
Shares Outstanding (Basic) | 265 | 264 | 263 | 261 | 260 | 253 | Upgrade |
Shares Outstanding (Diluted) | 265 | 264 | 266 | 266 | 265 | 259 | Upgrade |
Shares Change (YoY) | 0.02% | -0.61% | 0.08% | 0.17% | 2.27% | 2.23% | Upgrade |
EPS (Basic) | 1.02 | 1.31 | 2.29 | 2.00 | 2.10 | 1.80 | Upgrade |
EPS (Diluted) | 1.02 | 1.31 | 2.26 | 1.96 | 2.06 | 1.76 | Upgrade |
EPS Growth | -48.24% | -42.20% | 15.31% | -4.85% | 17.18% | 20.41% | Upgrade |
Free Cash Flow | 895 | 825 | 917 | 699 | 587 | 675 | Upgrade |
Free Cash Flow Per Share | 3.37 | 3.12 | 3.45 | 2.63 | 2.21 | 2.60 | Upgrade |
Dividend Per Share | 0.680 | 0.680 | 0.680 | 0.660 | 0.650 | 0.540 | Upgrade |
Dividend Growth | - | - | 3.03% | 1.54% | 20.37% | 17.39% | Upgrade |
Gross Margin | 52.94% | 52.84% | 49.47% | 48.72% | 48.80% | 47.77% | Upgrade |
Operating Margin | 4.18% | 5.05% | 6.22% | 6.39% | 7.90% | 8.82% | Upgrade |
Profit Margin | 2.01% | 2.52% | 4.21% | 4.31% | 6.14% | 6.40% | Upgrade |
Free Cash Flow Margin | 6.60% | 6.03% | 6.42% | 5.79% | 6.60% | 9.48% | Upgrade |
EBITDA | 833 | 957 | 1,143 | 945 | 748 | 643 | Upgrade |
EBITDA Margin | 6.14% | 6.99% | 8.00% | 7.83% | 8.41% | 9.03% | Upgrade |
D&A For EBITDA | 266 | 265 | 255 | 174 | 46 | 15 | Upgrade |
EBIT | 567 | 692 | 888 | 771 | 702 | 628 | Upgrade |
EBIT Margin | 4.18% | 5.05% | 6.22% | 6.39% | 7.90% | 8.82% | Upgrade |
Effective Tax Rate | 25.57% | 25.10% | 22.35% | 20.83% | 20.29% | 22.35% | Upgrade |
Revenue as Reported | 13,680 | 13,822 | 14,396 | 12,179 | 9,005 | 7,184 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.